These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17523616)

  • 1. Virtual screening studies to design potent CDK2-cyclin A inhibitors.
    Vadivelan S; Sinha BN; Irudayam SJ; Jagarlapudi SA
    J Chem Inf Model; 2007; 47(4):1526-35. PubMed ID: 17523616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potential ZAP-70 kinase inhibitors: pharmacophore design, database screening and docking studies.
    Sanam R; Vadivelan S; Tajne S; Narasu L; Rambabu G; Jagarlapudi SA
    Eur J Med Chem; 2009 Dec; 44(12):4793-800. PubMed ID: 19674816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An efficient tool for identifying inhibitors based on 3D-QSAR and docking using feature-shape pharmacophore of biologically active conformation--a case study with CDK2/cyclinA.
    Mascarenhas NM; Ghoshal N
    Eur J Med Chem; 2008 Dec; 43(12):2807-18. PubMed ID: 18037537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors.
    Ibrahim DA; El-Metwally AM
    Eur J Med Chem; 2010 Mar; 45(3):1158-66. PubMed ID: 20045222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural analysis of carboline derivatives as inhibitors of MAPKAP K2 using 3D QSAR and docking studies.
    Nayana RS; Bommisetty SK; Singh K; Bairy SK; Nunna S; Pramod A; Muttineni R
    J Chem Inf Model; 2009 Jan; 49(1):53-67. PubMed ID: 19119997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards more accurate pharmacophore modeling: Multicomplex-based comprehensive pharmacophore map and most-frequent-feature pharmacophore model of CDK2.
    Zou J; Xie HZ; Yang SY; Chen JJ; Ren JX; Wei YQ
    J Mol Graph Model; 2008 Nov; 27(4):430-8. PubMed ID: 18786843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knowledge based identification of MAO-B selective inhibitors using pharmacophore and structure based virtual screening models.
    Boppana K; Dubey PK; Jagarlapudi SA; Vadivelan S; Rambabu G
    Eur J Med Chem; 2009 Sep; 44(9):3584-90. PubMed ID: 19321235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into the structural basis of N2 and O6 substituted guanine derivatives as cyclin-dependent kinase 2 (CDK2) inhibitors: prediction of the binding modes and potency of the inhibitors by docking and ONIOM calculations.
    Alzate-Morales JH; Caballero J; Vergara Jague A; González Nilo FD
    J Chem Inf Model; 2009 Apr; 49(4):886-99. PubMed ID: 19323453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacophore modeling and virtual screening studies to design some potential histone deacetylase inhibitors as new leads.
    Vadivelan S; Sinha BN; Rambabu G; Boppana K; Jagarlapudi SA
    J Mol Graph Model; 2008 Feb; 26(6):935-46. PubMed ID: 17707666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies.
    Yu H; Wang Z; Zhang L; Zhang J; Huang Q
    Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
    Ibrahim DA; Ismail NS
    Eur J Med Chem; 2011 Dec; 46(12):5825-32. PubMed ID: 22000924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP; McInnes C
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
    Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
    Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A virtual screening approach for thymidine monophosphate kinase inhibitors as antitubercular agents based on docking and pharmacophore models.
    Gopalakrishnan B; Aparna V; Jeevan J; Ravi M; Desiraju GR
    J Chem Inf Model; 2005; 45(4):1101-8. PubMed ID: 16045305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of cyclin-dependent kinase inhibitor, CR229, using structurebased drug screening.
    Kim MK; Min J; Choi BY; Lim H; Cho YH; Lee CH
    J Microbiol Biotechnol; 2007 Oct; 17(10):1712-6. PubMed ID: 18156791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors.
    Singh SK; Dessalew N; Bharatam PV
    Eur J Med Chem; 2006 Nov; 41(11):1310-9. PubMed ID: 16890327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A computational model of binding thermodynamics: the design of cyclin-dependent kinase 2 inhibitors.
    Sims PA; Wong CF; McCammon JA
    J Med Chem; 2003 Jul; 46(15):3314-25. PubMed ID: 12852762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A convenient synthesis and molecular modeling study of novel purine and pyrimidine derivatives as CDK2/cyclin A3 inhibitors.
    Elgazwy AS; Ismail NS; Elzahabi HS
    Bioorg Med Chem; 2010 Nov; 18(21):7639-50. PubMed ID: 20851615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different classes of novel Pfmrk specific inhibitors.
    Bhattacharjee AK; Geyer JA; Woodard CL; Kathcart AK; Nichols DA; Prigge ST; Li Z; Mott BT; Waters NC
    J Med Chem; 2004 Oct; 47(22):5418-26. PubMed ID: 15481979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure.
    Kawanishi N; Sugimoto T; Shibata J; Nakamura K; Masutani K; Ikuta M; Hirai H
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5122-6. PubMed ID: 16876403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.